| Primary |
| Burkitt's Lymphoma |
16.5% |
| Fluid Replacement |
10.1% |
| Sedation |
9.2% |
| Infection |
6.4% |
| Prophylaxis Against Graft Versus Host Disease |
6.4% |
| Prophylaxis |
5.5% |
| Mantle Cell Lymphoma |
4.6% |
| Ureteral Stent Insertion |
4.6% |
| Ureteral Stent Removal |
4.6% |
| Adenovirus Infection |
3.7% |
| Bone Marrow Failure |
3.7% |
| Diuretic Therapy |
3.7% |
| Pyrexia |
3.7% |
| Cytomegalovirus Infection |
2.8% |
| Electrolyte Substitution Therapy |
2.8% |
| Hiv Infection |
2.8% |
| Papilloma Viral Infection |
2.8% |
| Progressive Multifocal Leukoencephalopathy |
2.8% |
| Anticoagulant Therapy |
1.8% |
| Bk Virus Infection |
1.8% |
|
| Drug Ineffective For Unapproved Indication |
16.7% |
| Renal Failure |
8.3% |
| Abdominal Pain |
4.2% |
| Accidental Exposure To Product |
4.2% |
| Acute Myeloid Leukaemia Recurrent |
4.2% |
| Encephalopathy |
4.2% |
| Hallucination |
4.2% |
| Idiopathic Thrombocytopenic Purpura |
4.2% |
| Incorrect Drug Administration Rate |
4.2% |
| Inflammation |
4.2% |
| Iridocyclitis |
4.2% |
| Nausea |
4.2% |
| No Therapeutic Response |
4.2% |
| Osteonecrosis |
4.2% |
| Pancreatitis |
4.2% |
| Pyrexia |
4.2% |
| Rash |
4.2% |
| Renal Disorder |
4.2% |
| Renal Tubular Disorder |
4.2% |
| Skin Infection |
4.2% |
|
| Secondary |
| Burkitt's Lymphoma |
11.8% |
| Sedation |
9.4% |
| Fluid Replacement |
9.3% |
| Prophylaxis |
7.9% |
| Ureteral Stent Insertion |
7.7% |
| Ureteral Stent Removal |
7.7% |
| Infection |
7.5% |
| Prophylaxis Against Graft Versus Host Disease |
5.1% |
| Diuretic Therapy |
4.7% |
| Infection Prophylaxis |
4.6% |
| Pyrexia |
3.3% |
| Anticoagulant Therapy |
3.1% |
| Cytomegalovirus Infection |
3.1% |
| Insomnia |
3.1% |
| Electrolyte Substitution Therapy |
2.5% |
| Hiv Infection |
2.0% |
| Antiretroviral Therapy |
1.8% |
| Idiopathic Thrombocytopenic Purpura |
1.8% |
| Product Used For Unknown Indication |
1.8% |
| Cytomegalovirus Viraemia |
1.6% |
|
| Respiratory Failure |
22.4% |
| Drug Ineffective For Unapproved Indication |
6.9% |
| Encephalopathy |
6.9% |
| Viral Infection |
6.9% |
| Vomiting |
6.9% |
| Graft Versus Host Disease |
5.2% |
| Progressive Multifocal Leukoencephalopathy |
5.2% |
| Drug Ineffective |
3.4% |
| Neutropenia |
3.4% |
| Renal Failure |
3.4% |
| Renal Failure Acute |
3.4% |
| Renal Impairment |
3.4% |
| Sinusitis |
3.4% |
| Stomatitis |
3.4% |
| Subdural Effusion |
3.4% |
| Transfusion-related Acute Lung Injury |
3.4% |
| Vision Blurred |
3.4% |
| Accidental Exposure To Product |
1.7% |
| Aplasia Pure Red Cell |
1.7% |
| Blood Cholinesterase Decreased |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.2% |
| Hiv Infection |
11.0% |
| Prophylaxis |
10.0% |
| Antifungal Prophylaxis |
5.0% |
| Bone Marrow Conditioning Regimen |
4.9% |
| Prophylaxis Against Graft Versus Host Disease |
4.7% |
| Acute Lymphocytic Leukaemia |
4.2% |
| Infection Prophylaxis |
4.2% |
| Antiretroviral Therapy |
3.9% |
| Asthma |
3.2% |
| Drug Use For Unknown Indication |
2.8% |
| Progressive Multifocal Leukoencephalopathy |
2.3% |
| Acute Myeloid Leukaemia |
2.1% |
| Non-hodgkin's Lymphoma |
2.1% |
| Antiemetic Supportive Care |
1.9% |
| Graft Versus Host Disease |
1.9% |
| Hypertension |
1.9% |
| Oesophageal Candidiasis |
1.9% |
| Sepsis |
1.9% |
| Adenovirus Infection |
1.6% |
|
| Progressive Multifocal Leukoencephalopathy |
10.6% |
| Vomiting |
9.1% |
| Renal Failure |
7.6% |
| Thrombocytopenia |
7.6% |
| Type 1 Diabetes Mellitus |
7.6% |
| Death |
6.1% |
| Renal Disorder |
6.1% |
| Sepsis |
6.1% |
| Anaemia |
4.5% |
| Depressed Level Of Consciousness |
4.5% |
| Brain Injury |
3.0% |
| Drug Resistance |
3.0% |
| Encephalitis Cytomegalovirus |
3.0% |
| Grand Mal Convulsion |
3.0% |
| Histiocytosis Haematophagic |
3.0% |
| Nausea |
3.0% |
| Pyrexia |
3.0% |
| Stenotrophomonas Infection |
3.0% |
| Ventricular Tachycardia |
3.0% |
| Visual Impairment |
3.0% |
|
